Inconsistent ben- efits have been noted in clinical trials comparing intensive BP reduction (systolic <130 mmHg) and standard BP treatment goals (systolic <140 mmHg) for patients with previous coro- nary events and a history of hypertension and diabetes mel- litus, therefore justifying the currently recommended systolic target value of <140 mmHg.220 225 With regard to diastolic BP goals, targeting a value of <85 mmHg appears to be safe and has been shown in 3 randomized trials to improve the clinical outcomes of patients with a history of hypertension, diabe- tes mellitus, or multiple cardiovascular risk factors compared with higher diastolic values.226 228 Admittedly, no clinical trials to date have specifically assessed BP targets after CABG with respect to clinical outcomes. However, given the high inci- dence of diabetes mellitus and other cardiovascular risk fac- tors in the CABG population, a BP goal of <140/85 mmHg217 appears reasonable and broadly applicable to all patients who have undergone CABG. Achieving the BP goal for secondary prevention in the patient having undergone CABG requires an understanding of the effectiveness of pre-CABG antihypertensive therapies and the temporary reduction in BP that occurs during recovery from postoperative surgical circumstances such as anemia and reduced myocardial function. With an emphasis on BP con- trol in the broad context of secondary prevention measures, antihypertensive medication regimens and BP goals should be adapted to the individualized circumstances of each patient.198 BP patterns and the response to treatment can be best assessed with the use of home BP monitoring.229 Lifestyle measures such as exercise, reducing weight, and limiting sodium intake are useful adjunct measures in the post-CABG patient with hypertension. 